 | |
| Clinical data | |
|---|---|
| Trade names | Corwin, Carwin, Corwil, Xamtol |
| Routes of administration | By mouth[1] |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Oral: 5%[1] |
| Eliminationhalf-life | 16–27 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H25N3O5 |
| Molar mass | 339.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Xamoterol, sold under the brand namesCorwin,Carwin,Corwil, andXamtol among others, is acardiac stimulant which is used in the treatment ofheart failure.[2] It acts as aselectivepartial agonist of theβ1-adrenergic receptor with around 50%intrinsic sympathomimetic activity (ISA) (i.e.,intrinsic activity).[1][3][4][2] The drug has no significantβ2-adrenergic receptor agonistic activity.[5] Xamoterol provides cardiac stimulation at rest but acts as a blocker duringexercise.[6] It is takenby mouth.[1]
Xamoterol is not available in theUnited States.[7][8] It is marketed in theUnited Kingdom,Austria,Belgium, andLuxembourg.[8]
Xamoterol is ahydrophiliccompound with a predictedlog P of -0.31 to -1.11.[9][10][11][12] Due to its hydrophilicity, xamoterol does not cross theblood–brain barrier and has nocentral nervous system effects.[12] Hence, it is aperipherally selective drug.[12]
